Cargando…
Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema
BACKGROUND: The purpose of this study is to assess the effectiveness of topical nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids (intravitreal dexamethasone and peribulbar triamcinolone) in treating pseudophakic macular edema (PME). METHODS: Retrospective study of 33 eyes. Variables...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570006/ https://www.ncbi.nlm.nih.gov/pubmed/34740334 http://dx.doi.org/10.1186/s12886-021-02132-w |
_version_ | 1784594755699605504 |
---|---|
author | Obis, Javier Arias, Luis Lorenzo, Daniel Padron-Perez, Noel Garcia-Bru, Pere Cobos, Estefania Morwani, Rahul Caminal, Jose |
author_facet | Obis, Javier Arias, Luis Lorenzo, Daniel Padron-Perez, Noel Garcia-Bru, Pere Cobos, Estefania Morwani, Rahul Caminal, Jose |
author_sort | Obis, Javier |
collection | PubMed |
description | BACKGROUND: The purpose of this study is to assess the effectiveness of topical nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids (intravitreal dexamethasone and peribulbar triamcinolone) in treating pseudophakic macular edema (PME). METHODS: Retrospective study of 33 eyes. Variables included best corrected visual acuity (BCVA; logMAR scale) and central retinal thickness (CRT) and central choroidal thickness (CCT) assessed with swept-source OCT. All patients were initially prescribed topical NSAIDs and reevaluated after 2 months. If improvement in BCVA or CRT was noted, topical NSAIDs were continued until resolution. If no improvement was observed at 2 months or subsequent visits, intravitreal dexamethasone implant was performed. Patients who refused intravitreal treatment were offered peribulbar triamcinolone. RESULTS: After treatment with topical NSAIDs for a median of 2 months, BCVA increased significantly from 0.5 to 0.3 while CRT decreased significantly from 435 to 316 μm. PME resolved in 19 of the 33 eyes (57.6%). Of the 14 recalcitrant cases, 13 were treated with corticosteroids. Of these 13 cases, 9 (69.2%) resolved. BCVA increased non-significantly from 0.7 to 0.4. CRT and CCT decreased significantly from 492 to 317 μm and from 204 to 182 μm respectively. CONCLUSIONS: The overall success rate of the treatment algorithm was greater than 80%, a remarkable finding considering that no randomized study has yet been conducted to determine the optimal therapeutic protocol for PME. This is the first study to evaluate choroidal thickness in PME using SS-OCT, which could play a key role in its pathophysiology and provide useful information to improve the management of PME. |
format | Online Article Text |
id | pubmed-8570006 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85700062021-11-08 Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema Obis, Javier Arias, Luis Lorenzo, Daniel Padron-Perez, Noel Garcia-Bru, Pere Cobos, Estefania Morwani, Rahul Caminal, Jose BMC Ophthalmol Research BACKGROUND: The purpose of this study is to assess the effectiveness of topical nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids (intravitreal dexamethasone and peribulbar triamcinolone) in treating pseudophakic macular edema (PME). METHODS: Retrospective study of 33 eyes. Variables included best corrected visual acuity (BCVA; logMAR scale) and central retinal thickness (CRT) and central choroidal thickness (CCT) assessed with swept-source OCT. All patients were initially prescribed topical NSAIDs and reevaluated after 2 months. If improvement in BCVA or CRT was noted, topical NSAIDs were continued until resolution. If no improvement was observed at 2 months or subsequent visits, intravitreal dexamethasone implant was performed. Patients who refused intravitreal treatment were offered peribulbar triamcinolone. RESULTS: After treatment with topical NSAIDs for a median of 2 months, BCVA increased significantly from 0.5 to 0.3 while CRT decreased significantly from 435 to 316 μm. PME resolved in 19 of the 33 eyes (57.6%). Of the 14 recalcitrant cases, 13 were treated with corticosteroids. Of these 13 cases, 9 (69.2%) resolved. BCVA increased non-significantly from 0.7 to 0.4. CRT and CCT decreased significantly from 492 to 317 μm and from 204 to 182 μm respectively. CONCLUSIONS: The overall success rate of the treatment algorithm was greater than 80%, a remarkable finding considering that no randomized study has yet been conducted to determine the optimal therapeutic protocol for PME. This is the first study to evaluate choroidal thickness in PME using SS-OCT, which could play a key role in its pathophysiology and provide useful information to improve the management of PME. BioMed Central 2021-11-05 /pmc/articles/PMC8570006/ /pubmed/34740334 http://dx.doi.org/10.1186/s12886-021-02132-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Obis, Javier Arias, Luis Lorenzo, Daniel Padron-Perez, Noel Garcia-Bru, Pere Cobos, Estefania Morwani, Rahul Caminal, Jose Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema |
title | Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema |
title_full | Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema |
title_fullStr | Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema |
title_full_unstemmed | Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema |
title_short | Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema |
title_sort | topical nsaids, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570006/ https://www.ncbi.nlm.nih.gov/pubmed/34740334 http://dx.doi.org/10.1186/s12886-021-02132-w |
work_keys_str_mv | AT obisjavier topicalnsaidsintravitrealdexamethasoneandperibulbartriamcinoloneforpseudophakicmacularedema AT ariasluis topicalnsaidsintravitrealdexamethasoneandperibulbartriamcinoloneforpseudophakicmacularedema AT lorenzodaniel topicalnsaidsintravitrealdexamethasoneandperibulbartriamcinoloneforpseudophakicmacularedema AT padronpereznoel topicalnsaidsintravitrealdexamethasoneandperibulbartriamcinoloneforpseudophakicmacularedema AT garciabrupere topicalnsaidsintravitrealdexamethasoneandperibulbartriamcinoloneforpseudophakicmacularedema AT cobosestefania topicalnsaidsintravitrealdexamethasoneandperibulbartriamcinoloneforpseudophakicmacularedema AT morwanirahul topicalnsaidsintravitrealdexamethasoneandperibulbartriamcinoloneforpseudophakicmacularedema AT caminaljose topicalnsaidsintravitrealdexamethasoneandperibulbartriamcinoloneforpseudophakicmacularedema |